Perioperative Endothelial Dysfunction
Perioperative Endothelial Dysfunction in Patients Undergoing Non-cardiac Surgery
More than one in 100 otherwise healthy patients undergoing non-cardiac surgery will die within 30 days post-operatively, and of these patients 45% will die from vascular causes such as myocardial infarction. The pathogenesis of perioperative myocardial infarction is complex and to date not fully elucidated. The physiological stress response associated with the surgical procedure is believed to be central in the development of perioperative cardiovascular complications. Surgery initiates systemic inflammation, hypercoagulability and increases the production of catecholamines and cortisol. These drastic systemic changes lead to a state of myocardial oxygen supply-demand mismatch, which added to acute endothelial dysfunction and ruptures of vulnerable plaques, may result in myocardial injury.
The endothelium is a regulator of vascular homeostasis, vascular tone and structure and exerts anticoagulant, antiplatelet and fibrinolytic properties. Endothelial dysfunction is characterized by a decreased vascular bioavailability of nitric oxide probably due to an increased degradation of nitric oxide via its interaction with locally produced reactive oxygen species. No clinical studies have investigated whether peri- and postoperative endothelial dysfunction is associated with an increased risk of perioperative myocardial injury. Endothelial dysfunction may be a key element in the development of perioperative myocardial injury.
The aim of this observational clinical study is to closely examine the endothelial function and its dynamics in the early postoperative period.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Roskilde, Denmark, 4000
- Department of Surgery, Roskilde Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
• Patients scheduled for elective colon cancer surgery
Exclusion Criteria:
- Not capable of giving informed consent after oral and written information
- Previously included in the trial
- Surgery within 7 days of the trial
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline endothelial function (reactive hyperemia index) at 4 days postoperatively
Time Frame: baseline before operation, 4 hours postoperatively and daily assessments day 1-4 after surgery.
|
The reactive hyperemia index is assessed non-invasively by the EndoPat system.
|
baseline before operation, 4 hours postoperatively and daily assessments day 1-4 after surgery.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Biomarkers of endothelial function: plasma arginine, plasma asymmetric dimethylarginine and plasma tetrahydrobiopterin
Time Frame: before surgery, 4 hours postoperatively and daily assessments on day 1-4 after surgery
|
before surgery, 4 hours postoperatively and daily assessments on day 1-4 after surgery
|
|
Biomarkers of endothelial glycocalyx degradation (syndecan-1, atrial natriuretic peptide)
Time Frame: before surgery, 4 hours postoperatively and daily assessments on day 1-4 after surgery.
|
before surgery, 4 hours postoperatively and daily assessments on day 1-4 after surgery.
|
|
Plasma cardiac troponin I
Time Frame: before surgery and one daily assessment on day 1-4 after surgery.
|
before surgery and one daily assessment on day 1-4 after surgery.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sarah E Busch, MD, Department of Surgery, Koge University Hospital, Denmark
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SBpoetry
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.